dihydrofolate

Trimethoprim (NSC-106568) is a Dihydrofolate Reductase Inhibitor Antibacterial. The mechanism of action of trimethoprim is as a Dihydrofolate Reductase Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Organic Cation Transporter 2 Inhibitor.

Dihydrofolic acid (7,8-Dihydrofolic acid) is a folic acid derivative that produces tetrahydrofolic acid in the presence of dihydrofolic acid reductase.

10-Formyldihydrofolate is a Methotrexate metabolite. It inhibits thymidylate synthetase and glycinamide ribotide transformylase.

5-Methyldihydrofolate is the primary biologically active form of folate used for DNA reproduction, the cysteine cycle, and the regulation of homocysteine.

WR99210 hydrochloride is a potent inhibitor of Plasmodium falciparum dihydrofolate reductase (pfDHFR), which is a major malarial drug target. It has subnanomolar potency for the wild type, double mutant and quadruple mutant dihydrofolate reductases.

CPS-11 (N-(Hydroxymethyl)thalidomide) is a Thalidomide analogue with significant antitumor activity, exhibiting a broader and more potent effect on the MM (multiple myeloma) cell line.

Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma and metastatic breast cancer.

Methotrexate Diglutamate Small molecule compound present in the liver that acts as a partially purified human dihydrofolate reductase inhibitor.

Talotrexin ammonium is a non-polyglutamic acid antifolate. Talotrexin ammonium inhibits tumor growth by targeting dihydrofolate reductase (DHFR), thereby improving anti-tumor activity in a wide range of cancer models, helping to inhibit tumor growth.

Pyrimethamine (Pirimecidan) is a competitive inhibitor of dihydrofolate reductase (DHFR), used as an antimalarial drug.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors.

Methotrexate disodium is an tetrahydrofolate dehydrogenase inhibitor

Epiroprim (Ro11-8958) is a selective dihydrofolate reductase (DHFR) inhibitor with antibacterial activity, inhibiting Staphylococcus, Enterococcus, Pneumococcus, and Streptococcus.

Phototrexate is a photoswitchable potent inhibitor of human dihydrofolate reductase (DHFR). Phototrexate is a photochromic analog of Methotrexate. Antifolate activity is switched on (cis-Phototrexate) by UVA (375 nm) light; it can be switched off (trans-Phototrexate) by blue or white light and by thermal relaxation in the dark.cis-Phototrexate (IC50 = 6 nM) significantly reduces the viability of HeLa cells compared withtrans-Phototrexate (IC50 = 34 μM).

Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM, a hDHFR IC50 of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196.

DHFR-IN-3 (7-bromoquinazoline-2,4-diamine) is a dihydrofolate reductase (DHFR) inhibitor.

Cycloguanil hydrochloride (Chloroguanide Triazine) is an active metabolite of the antimalarial compound proguanil. It acts as an inhibitor of dihydrofolate reductase (Kis: 0.3 and 1.5 nM for Plasmodium and human forms, respectively).

Cycloguanil D6 Nitrate is a dihydrofolate reductase inhibitor, deuterium-labeled Cycloguanil.

Cycloguanil D6 is a dihydrofolate reductase inhibitor, deuterium-labeled Cycloguanil.

Ro 20-0657 000 is a metabolite of Trimethoprim, an inhibitor of dihydrofolate reductase and an antibacterial agent used in human and veterinary medicine.

Trimetrexate is an effective competitive inhibitor of bacterial, protozoan, and mammalian dihydrofolate reductase.

WR99210 (BRL 6231 free base) is an orally available dihydrofolate reductase (DHFR) inhibitor with antiparasitic activity, often used in combination with dapsone to study Mycobacterium avium complex (MAC).

DHFR-IN-20 (Compound LA1) is an inhibitor of dihydrofolate reductase (DHFR) targeting the malignant strains of the malaria parasite. It exhibits inhibition constants (Kis) of 0.16 nM, 0.30 nM, and 6.6 nM for PfDHFR-WT, PfDHFR-QM, and HsDHFR, respectively. Additionally, DHFR-IN-20 demonstrates antimalarial activity, with IC50 values of 1.4 nM against parasites carrying the wild-type (TM4 8.2) PfDHFR enzyme and 1.6 μM against those with the quadruple mutation (V1 S)PfDHFR.